Oruka Therapeutics (ORKA) Stock Price, News & Analysis

Company Overview

Oruka Therapeutics, Inc. is a clinical‐stage biopharmaceutical company focused on the development of novel peptide‐based therapies for oncology. The company’s proprietary stapled peptide platform is designed to selectively disrupt intracellular protein–protein interactions that drive tumor growth and immune evasion. By combining the specificity of biologics with the cell‐permeability of small molecules, Oruka aims to target cancer pathways that have been historically considered “undruggable.”

The company’s lead candidate, ONCT-01, is currently in Phase 1 clinical trials for patients with advanced solid tumors, assessing safety, tolerability and preliminary efficacy. In addition to ONCT-01, Oruka’s pipeline includes multiple preclinical programs directed at key targets such as MDM2-p53 and MYC, reflecting a broad strategy to address unmet needs across various tumor types. The company’s research efforts extend to both monotherapy and combination therapy approaches to enhance anti‐tumor activity.

Headquartered in the United States, Oruka Therapeutics became a publicly traded company in 2022 and is listed on the NASDAQ under the symbol ORKA. The organization is led by a management team with extensive experience in peptide chemistry, oncology drug development and clinical operations. Oruka continues to advance its technology platform and pipeline toward the goal of delivering innovative cancer treatments to patients worldwide.

Key Stats

• Today's Range: $68.60 to $71.00
• 50-Day Range: $31.99 to $76.39
• 52-Week Range: $8.91 to $91.00
• Volume: 655,874 shs
• Average Volume: 1.00 million shs
• Market Capitalization: $3.48 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $120.80
• Consensus Rating: Moderate Buy

Oruka Therapeutics Stock Analysis - MarketRank™

Oruka Therapeutics scored higher than 65% of companies evaluated by MarketBeat, and ranked 260th out of 856 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Oruka Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.82, and is based on no strong buy ratings, 10 buy ratings, no hold ratings, and 1 sell rating.

Upside Potential

Oruka Therapeutics has a consensus price target of $120.80, representing about 72.3% upside from its current price of $70.11.

Amount of Analyst Coverage

Oruka Therapeutics has been the subject of 9 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Oruka Therapeutics are expected to decrease in the coming year, from ($2.20) to ($2.59) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Oruka Therapeutics is -37.71, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Oruka Therapeutics is -37.71, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Oruka Therapeutics has a P/B Ratio of 7.24. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

14.65% of the float of Oruka Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Oruka Therapeutics has a short interest ratio ("days to cover") of 4.04.

Change versus previous month

Short interest in Oruka Therapeutics has recently increased by 22.43%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Oruka Therapeutics does not currently pay a dividend.

Dividend Growth

Oruka Therapeutics does not have a long track record of dividend growth.

News and Social Media

• Score: 4.2 / 5
• News Sentiment: 0.75

News Sentiment

Oruka Therapeutics has a news sentiment score of 0.75. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.56 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 20 news articles for Oruka Therapeutics this week, compared to 4 articles on an average week.

Search Interest

10 people have searched for ORKA on MarketBeat in the last 30 days. This is an increase of 900% compared to the previous 30 days.

MarketBeat Follows

3 people have added Oruka Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days.

Company Ownership

• Score: 2.1 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Oruka Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,089,745.00 in company stock.

Percentage Held by Insiders

23.49% of the stock of Oruka Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

56.44% of the stock of Oruka Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

ORKA Stock Analysis - Frequently Asked Questions

How have ORKA shares performed this year?

Oruka Therapeutics' stock was trading at $30.31 at the start of the year. Since then, ORKA stock has increased by 131.3% and is now trading at $70.11.

How were Oruka Therapeutics' earnings last quarter?

Oruka Therapeutics, Inc. (NASDAQ:ORKA) announced its quarterly earnings data on Thursday, March, 12th. The company reported ($0.45) EPS for the quarter, topping analysts' consensus estimates of ($0.61) by $0.16.

Who are Oruka Therapeutics' major shareholders?

Top institutional shareholders of Oruka Therapeutics include Candriam S.C.A. (0.82%), Bank of New York Mellon Corp (0.21%), Y Intercept Hong Kong Ltd (0.07%) and Empirical Financial Services LLC d.b.a. Empirical Wealth Management (0.04%). Insiders that own company stock include Venrock Healthcare Capital Par, Lawrence Otto Klein, Joana Goncalves and Arjun Agarwal.
View institutional ownership trends.

How do I buy shares of Oruka Therapeutics?

Shares of ORKA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Oruka Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Oruka Therapeutics investors own include Astria Therapeutics (ATXS), Aldeyra Therapeutics (ALDX), Black Diamond Therapeutics (BDTX), Energy Transfer (ET), Heron Therapeutics (HRTX), Skye Bioscience (SKYE) and NuScale Power (SMR).

Company Calendar

• Last Earnings: 3/12/2026
• Today: 5/06/2026
• Next Earnings (Estimated): 5/13/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - DRUGS
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:ORKA
• Previous Symbol: NASDAQ:ORKA
• CIK: 907654
• Web: www.arcabio.com
• Phone: 720-940-2100
• Fax: 720-208-9261
• Employees: N/A
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Oruka Therapeutics: $120.80
• High Price Target: $200.00
• Low Price Target: $45.00
• Potential Upside/Downside: +73.5%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.82
• Research Coverage: 11 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.86)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$105.43 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -25.48%
• Return on Assets: -24.34%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 22.37
• Quick Ratio: 22.37

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $9.69 per share
• Price / Book: 7.18

Miscellaneous

• Outstanding Shares: 50,200,000
• Free Float: 38,406,000
• Market Cap: $3.49 billion
• Optionable: N/A
• Beta: -0.20